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Abstract 
Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, 
associated with the production of a monoclonal immunoglobulin (M protein) which can be detected 
in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in 
MM pathogenesis, and several studies have identified single nucleotide polymorphisms (SNPs) 
associated with the susceptibility to the disease. SNPs within miRNA-binding sites in target genes 
(miRSNPs) may alter the strength of miRNA–mRNA interactions, thus deregulating protein 
expression. MiRSNPs are known to be associated with risk of various types of cancer, but they have 
never been investigated in MM. We performed an in silico genome-wide search for miRSNPs 
predicted to alter binding of miRNAs to their target sequences.  We selected 12 miRSNPs and 
tested their association with MM risk. Our study population consisted of 1,832 controls and 2,894 
MM cases recruited from 7 European countries and Israel in the context of the IMMEnSE 
(International Multiple Myeloma rESEarch) consortium. In this population two SNPs showed an 
association with p<0.05: rs286595 (located in gene MRLP22) and rs14191881 (located in gene 
TCF19). Results from IMMEnSE were meta-analyzed with data from a previously published 
genome-wide association study (GWAS). The SNPs rs13409 (located in the 3’UTR of the POU5F1 
gene), rs1419881 (TCF19), rs1049633, rs1049623 (both in DDR1) showed significant associations 
with MM risk. In conclusion, we sought to identify genetic polymorphisms associated with MM 
risk starting from genome-wide prediction of miRSNPs. For some mirSNPs we have shown 
promising associations with MM risk. 
 
What's new? Even though deregulation of miRNA expression has been associated with human 
cancers little information is available regarding their relation with MM susceptibility. We performed 
an in silico genome-wide search for miRSNPs and selected the most promising ones for an 
association study. The SNPs with the strongest associations with MM risk are localized in genes 
which have never been related with MM.  
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Introduction 
Multiple myeloma (MM) is a malignancy of plasma cells, usually infiltrating the bone marrow, 
and associated with the production of a monoclonal immunoglobulin (M protein) which can be 
detected in the blood and/or urine. MM affects the places where bone marrow is normally active in 
an adult. MM is a relatively infrequent cancer among both sexes. On a worldwide scale, it is 
estimated that about 86,000 incident cases occur annually, accounting for about 0.8% of all new 
cancer cases. About 63,000 subjects are reported to die from the disease each year, accounting for 
0.9% of all cancer deaths and nearly 10% of all haematological neoplastic diseases. 
Several factors are known or suspected to cause myeloma or trigger an already abnormal or 
damaged pre-myeloma cell population in the bone marrow. Exposure to toxic chemicals, ionizing 
radiations, immunodeficiency, or infection with cancer-causing viruses have all been implicated as 
causes or triggers of MM
1
. Converging evidence of MM in monozygotic twins and familial 
aggregation of MM strongly suggest that MM aetiology has a robust genetic component as well
2
. 
Several risk loci have been proposed and a few have been identified through candidate gene and 
genome-wide association studies (GWAS)
3–10
.  Some of these loci are involved in complex 
pathways related to cell cycle, cell proliferation and DNA repair, in which micro-RNAs (miRNAs) 
have a proven regulatory role
11
.  
MiRNAs are small non-coding RNA molecules, 20-25 nucleotides long, highly conserved 
throughout evolution. In mammals, miRNAs are predicted to control the activity of more than 60% 
of all protein-coding genes and participate in the regulation of almost every cellular process 
investigated to date
12
. They play a major role in post-transcriptional regulation processes, mainly 
silencing target mRNAs and thus decreasing their corresponding protein expression
13
.  
These small RNAs post-transcriptionally repress gene expression by recognizing 
complementary target sites most often in the 3' untranslated region (UTR) of target messenger 
RNAs (mRNAs). Several miRNAs were found to be directly involved in human cancers, including 
lung, breast, brain, liver, colon cancer and leukemia. In addition, some miRNAs may function as 
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oncogenes or tumor suppressors in tumor development. Furthermore, a widespread down-regulation 
of miRNAs is commonly observed in human cancers, which promotes cellular transformation and 
tumorigenesis
14–17
.  Recent studies have revealed a role of miRNAs in MM. Deregulated miRNA 
expression in plasma cells has been associated with tumor progression, molecular subtypes, clinical 
staging, prognosis, and drug response in MM
18
. 
Although mutation in miRNA seed sequence seems to be a rare event, sequence variation in 
miRNA target sites is relatively frequent and may play a role in cancer etiology. In silico analyses of 
expressed sequence tag SNP databases indicate different allele frequencies of miRNA-binding sites 
in tumors versus normal tissues
19
. Polymorphisms in miRNA-binding sites in target genes may alter 
the strength of miRNA–mRNA interactions, thus deregulating protein expression. SNPs belonging 
to this category are called miRSNPs
20
. MiRSNPs have been shown to be associated with the risk of 
several cancers 
21–23
  . 
We hypothesize that miRSNPs may have a role in the susceptibility of MM. To this aim, we 
performed an in silico genome-wide search of miRSNPs predicted to affect binding of micro-RNAs 
to their target genes and tested the most promising ones in a case-control association study.  
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Materials and methods 
Study population 
The study population consisted of 1,832 controls and 2,894 MM cases recruited from 7 
European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma 
rESEarch) consortium (table 1)
24
 . 
Diagnosis of patients with symptomatic MM was carried out by haematologists according to 
the International Myeloma Working Group (IMWG) criteria. Demographic and clinicopathological 
characteristics including age, gender, country of origin, disease stage (Durie-Salmon and/or 
International Staging System) and serum creatinine levels were retrospectively gathered from 
medical records in each participant institution. 
Controls were selected among the general population (Italian), blood donors (Danish, Spanish, 
Polish, Portuguese and French), and hospitalized subjects with different diagnoses excluding cancer 
(Hungarian, Spanish). Gender and age at recruitment were collected for every subject enrolled. 
Cases and controls are not matched individually but age distribution and sex ratio were similar 
between cases and controls (table 1). Control samples have been collected in the same centers of the 
cases, or at least in the same geographic areas. 
In keeping with the guidelines of the Declaration of Helsinki, written informed consent was 
obtained from each participant and approval for collection and use of the samples was obtained 
from local Institutional Review Boards. 
 
SNP selection criteria  
 A search for mirSNPs was carried out on the whole genome. Polymorphisms were selected 
using bioinformatic tools and consultation of results of a previously published GWAS on MM risk. 
The selection of miRSNPs was conducted with the following criteria (Figure 1): 
• location in 3’UTR of known genes 
• high conservation score, ≥ +1 
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• MAF (minor allele frequency ) ≥ 0.05 in Caucasians 
• the strength of binding between each miRNA and its target sequence with the major and 
the minor allele (measured in silico), using mrSNP 
25
 
• location in genes that are expressed in MM cells, using Oncomine 
26
 
 
Putative miRNA-binding sites within the 3’UTR (defined as transcribed sequences from the 
stop codon to the end of the last exon of each gene) were detected by jSNPSelector version 1.0.1.7 
(http://sourceforge.net/projects/jsnpselector/), a custom-made algorithm that interrogates the 
ENSEMBL database. The conservation score is assigned to each nucleotide in a multiple species 
alignment to determine how conserved the nucleotide is. 
The strength of binding with the major and the minor allele was measured in silico using the 
publicly available mrSNP software (http://mrsnp.osu.edu). mrSNP showed a good performance to 
predict SNPs experimentally validated to affect miRNA binding, correctly identifying 69% (11/16) 
of the SNPs disrupting binding
25
.  
The selection with the mentioned workflow resulted in a list of 394 SNPs with high difference 
in Gibbs free energy between the two alleles (∆∆G) (Supplementary table 1). For mirSNPs 
predicted to bind more than one miRNA, we summed up all the ∆∆Gs for each miRNA, obtaining 
thus a total ∆∆G.  
As a final step, we verified if these miRSNPs were associated with MM risk in a previously 
published GWAS data set
4,6
.  
 Based on the process described above, we started from 2,817 SNPs, and we finally selected 12 
SNPs reported in table 2. The final list included 3 SNPs (rs1050239, rs735794 and rs1052536) with 
highest predicted difference between the two alleles in the strength of binding between miRNAs 
and their target sequence (total ∆∆G), regardless of association in the previously performed GWAS, 
with a threshold of total ∆∆G>550 (another SNP, rs13505, had ∆∆G>550 as shown in 
supplementary table 1, but it could not be designed as TaqMan assay and was therefore excluded). 
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Three more SNPs (rs1803275, rs12509103, rs3197716) had both a high total ∆∆G (∆∆G>300) and 
p<0.05 for association with MM risk in the GWAS. The other 6 SNPs were selected according to 
the GWAS p-value criterion, regardless of total ∆∆G, with an arbitrary threshold of p<0.005. 
 
SNP genotyping, quality control and data filtering 
Genomic DNA was extracted from peripheral blood or whole blood of MM cases and controls, 
using QIAampR 96 DNA QIAcubeR HT Kit. A whole genome amplification was carried out on 
samples with low levels of DNA. All the genotyping assays were carried out in 384-well format, 
with 10 ng of DNA from each subject. The order of DNAs from cases and controls was randomized 
on plates in order to ensure that an equal number of cases and controls was analyzed 
simultaneously. For quality control purpose, duplicates of 10% of the samples were interspersed 
throughout the plates. Genotyping of the 12 selected miRSNPs was carried out by using the 
TaqMan Real Time PCR method. The quality of the genotype data was assessed on the basis of 
sample call rates (we accepted samples with at least 8 out of 12 SNPs successfully genotyped), 
concordance rates between duplicate DNAs (≥99%) and test for Hardy-Weinberg Equilibrium 
(HWE) among controls in each population. We applied a Bonferroni correction for multiple testing 
to calculate the significance threshold for HWE: 0.05/(12 SNPs x 8 countries) = 5.2x10
-4
.  
 
Statistical analysis  
Analysis of association between SNPs and MM risk was performed with multivariate logistic 
regression models, adjusting for a set of covariates including age (at diagnosis for MM cases, at 
recruitment for controls), gender and country of origin. The association between miRSNPs and MM 
risk was calculated by estimating odds ratios (OR) and their 95% confidence intervals (C.I.). For all 
genotypes, we performed a statistical analysis with the allelic, dominant, codominant and recessive 
models. Since 3 of our SNPs (rs1049633, rs1049628, rs1049623) were located in the same gene 
DDR1 (r
2
 ranging from 0.377 to 0.237 in Caucasians) and two more SNPs (rs1419881 and rs13409) 
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are physically close to each other (r
2
=0.887), we calculated also MEFF correction. MEFF  is a simple 
correction for multiple testing of SNPs in linkage disequilibrium (LD) with each other, based on the 
spectral decomposition of matrices of pairwise LD between SNPs
27
. This method provides a useful 
alternative to more computationally intensive permutation tests. For performing this correction we 
used an interface available online (http://gump.qimr.edu.au/general/daleN/SNPSpD). We found a 
MEFF = 11.50. 
A P-value below 0.001, calculated with the formula 0.05/(11.5x4) was considered as threshold 
of statistical significance, considering the Bonferroni correction for MEFF and the number of 
inheritance models tested. 
Finally, we performed a meta-analysis between the data obtained in IMMEnSE and the data 
from two GWAS, respectively conducted in German and English populations
4,6
 . We considered the 
different countries participating in IMMEnSE and in the GWAS as separate groups and carried out 
meta-analyses according to the fixed effects model. 
All the statistical analyses were carried out using STATA software, version 11 for Windows.  
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Results  
IMMeNSE. As showed in table 3, we did not find strong associations between SNPs and MM 
risk. Table 3 reports the results of the analyses performed according to an allelic and codominant 
inheritance model. Two SNPs showed a p-value < 0.05: rs286595 (located in gene MRLP22) and 
rs14191881 (located in gene TCF19). Analyses of recessive and dominant models did not show any 
association at the level of 0.05 or below (data not shown). For all the analyses none of the SNPs 
passed the threshold of significance after correction for multiple testing. 
Meta-analysis. We performed a meta-analysis between the results from IMMEnSE and the 
published data of two GWASs conducted in the English and the German populations, respectively, 
for a total of 1,675 MM cases and 5,903 controls. Complete results are shown in supplementary 
table 2. We found p-values <10
-3
 for the SNPs rs13409, rs1049623, rs1049633 and rs1419881 
according to allelic or co-dominant model and no or minor heterogeneity, suggesting an association 
with a decreased risk of MM (table 4).  
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Discussion and conclusion  
The first steps of our study were the selection of the SNPs and the genotyping of cases and 
controls in the context of the IMMEnSE consortium. Although the sample size was adequate, none 
of the statistical analyses passed the significance threshold after the correction for multiple testing. 
However SNPs rs286595 (MRPL22) and rs14191881 (TCF19) showed a p-value < 0.05. The latter 
came up also in the meta-analysis, as did the SNPs rs1049633, rs1049623 (both located in the 
3’UTR of the DDR1) and rs13409 (POU1F5), which all showed an association with a decreased 
risk of MM, with no heterogeneity between IMMEnSE and the GWAS except for one case 
(rs1049633, pheterogeneity=0.038).  
The protein encoded by the gene DDR1 belongs to a subfamily of tyrosine kinase receptors that 
are activated by various types of collagen. Upregulation of DDR1 in multiple human cancers 
implies that DDR1 is involved in tumor progression 
28–30
. Four different miRNAs are predicted to 
bind DDR1 at the location of rs1049633: miR-2355-3p, miR-7, miR-3915, miR-4689. When A 
substitutes G, miR-2355-3p and miR-4689 are predicted to bind more tightly to the DDR1 3’UTR, 
instead, for miR-7 and miR-3915 the A allele is predicted to decrease its binding affinity. 
MicroRNA-7 (miR-7) acts as a potential tumor suppressor, but the opposite effect also has been 
reported
31
. MiR-7 regulates diverse fundamental biological processes of cancer cells including 
initiation, proliferation, migration, invasion, survival and death by targeting a number of oncogenic 
signaling pathways. Two miRNAs are predicted to bind the DDR1 gene where the SNP rs1049623 
is located: miR-4499 and miR-4513. We found out that carriers of C allele show a decreased risk of 
MM. The binding force of miRNAs for this SNP is predicted to be stronger when this allele is 
present, therefore it may be that when a C is present DDR1 is down-regulated, whereas usually this 
gene is up-regulated in cancer 
32
. Thus, the association we observed is consistent with the known 
biological function of DDR1. 
SNP rs1419881 is located in the gene TCF19 (transcription factor 19), which encodes a protein 
containing a PHD-type zinc finger domain and likely functions as a transcription factor. TCF19 was 
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found to be involved in cell cycle progression and proliferation in the pancreatic β-cell and it plays 
a role in the pathogenesis of diabetes
33
. Type 2 diabetes has been frequently associated with MM 
and it is thought to influence the myelomagenesis through hyperglycaemia and insulin-dependent 
and -independent mechanisms
34
. Moreover, rs1419881 is in linkage disequilibrium (r
2
=0.82) with 
the SNP rs3130453 which is located in the gene CCHCR, also known as HCR (Supplementary table 
2). The detailed function of the gene is still largely unknown. In particular, rs3130453 creates either 
a codon for tryptophan (G) or a stop codon (A). The stop codon (allele Iso3) results in the shorter 
isoform whereas the codon for tryptophan enables the usage of an earlier translation start site in 
exon 1b, thus leading to a protein with 89 additional amino acids in its N-terminal domain
35
. The 
most significant association in our analyses was found in the codominant model (p = 0.0002), 
where carriers of AA genotype have a decreased risk of MM.  
The gene POU5F1, where rs13409 is located, encodes a transcription factor containing a POU 
homeodomain that plays a key role in embryonic development and stem cell pluripotency. 
Interestingly, POU5F1 is also named as OCT-4 and it is one of the four main factors involved in the 
formation of the induced pluripotent stem cells
36
. It has a pivotal role in the maintenance of the 
differentiation status of, in practice, all types of cells and its regulation could be very important also 
for maintaining the appropriate differential state in B lymphocytes. 
This study has several strengths: large sample size and systematic, genome-wide search for 
miRSNPs. The genome-wide approach ensures that the whole set of common miRSNPs has been 
considered for this study. We cannot exclude that rarer miRSNPs have a role in MM risk, but a 
much larger sample size would be needed to address this issue. 
Predictions of miRNA-mRNA binding were carried out only with in silico tools and not 
experimentally confirmed. This could be a weakness of the study. Moreover, the vast majority of 
study subjects were Caucasians, thus it is not clear if these results can be generalized to other 
populations as well. Finally, the associations were largely driven by the German component of the 
GWAS results, and were weaker in IMMEnSE and in the English GWAS. Indeed, when the 
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German population is excluded from the meta-analysis none of the SNPs were significant 
associated with MM risk considering a Bonferroni-corrected threshold, although rs286595 was 
associated with p<0.05 (supplementary table 3). Thus, the results of the meta-analysis should be 
taken with caution. However, we did not observe statistically significant heterogeneity among the 
IMMEnSE subgroups and the GWAS populations (except for rs1049633, pheterogeneity=0.038). 
In conclusion, we found promising associations between mirSNPs in DDR1, TCF19, POU5F1 
and MM risk, which should be further replicated in independent studies. If these associations are 
confirmed, it would be interesting to test the function of the SNPs with in vitro and in vivo studies.  
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Table 1. Description of the study population. 
 
 Cases Controls Total 
Geographic origin
a
    
Denmark 299 489 788 
France 360 176 536 
Hungary 155 101 256 
Israel 93 97 190 
Italy 298 228 526 
Poland 1,254 227 1.481 
Portugal    152 195 347 
Spain 283 319 602 
Total 2,894 1,832 4,726 
Median age 
(25%-75% percentiles) 
62 (55-68) 53 (42-65)  
Gender
b
    
     Males 1,378 991 2,414 
     Females 1,302 841 2,159 
 
a Italy: Department of Oncology, Transplants and Advanced Technologies, Section of  Hematology, Pisa University Hospital, Pisa; 
Department of Biology, Division of Genetics, Pisa University, Pisa. 
Poland: Department of Hematology, Medical University of Lodz, Lodz; Department of Hematology, Cracow University Hospital, 
Cracow; Rzeszow Regional Hospital, Rzeszow; Holy Cross Cancer Center, Kielce; Hematology Clinic, Wroclaw; Department of 
Hematology, Municipal Hospital, Torun; Gdynia Oncology Center, Gdynia; Hematooncology Clinic, Lublin; Military Medical 
Institute, Warsaw; Rydygiera Hospital, Cracow; University Hospital, Bydgoszcz; Municipal Hospital, Katowice 
Spain: Hematology division, University Hospital of Salamanca, Salamanca; Hematology and Hemotherapy Department, University 
Hospital Virgen de las Nieves, Granada; Hospital Universitario Doce de Octubre, Madrid; Hospital General Universitario Morales 
Meseguer, Murcia. 
France: Hospices Civils de Lyon, International Agency for Research on cancer (IARC), Lyon. 
Portugal: Hospital de Braga, University of Minho, Braga. 
Hungary: Department of Internal Medicine, Sammelweis University, Budapest. 
Denmark: Department of Hematology, Roskilde Hospital, Copenhagen University, Roskilde;  
Israel: Hematology Division, Sheba Medical Center, Tel Hashomer.  
b The sum does not add up to the total of subjects due to missing data. 
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Table 2. List of the selected SNPs. 
 
miRSNP Gene Alleles 
Chromosome 
position 
Total ∆∆G 
P-value 
(GWAS) 
Regulome
a
 
rs735794 SH3BP2 G>C 4:2,837,711 604.1 0.61608 
2b: TF binding + any 
motif + DNase Footprint 
+ DNase peak 
rs12509103 MFAP3L A>T 4:169,986,644 315.4 0.016448 
3a: TF binding + any 
motif + DNase peak 
rs286595 MRPL22 C>T 5:154,968,992 171.3 0.0034897 
3a: TF binding + any 
motif + DNase peak 
rs1049623 DDR1 T>C 6:30,897,052 53.4 0.00014557 
5: TF binding or DNase 
peak 
rs1049633 DDR1 G>A 6:30,898,750 132.4 0.0017839 
1f: eQTL + TF binding / 
DNase peak 
rs1049628 DDR1 C>T 6:30,899,329 182.2 0.0050759 
5: TF binding or DNase 
peak 
rs1419881 TCF19 G>A 6:31,162,816 340.3 0.00094442 
1f: eQTL + TF binding / 
DNase peak 
rs13409 POU5F1 G>A 6:31,164,363 164.1 0.0009308 
4: TF binding + DNase 
peak 
rs1050239 SMPD1 G>A 11:6,394,233  638.6 0.74808 
5. TF binding or DNase 
peak 
rs11628336 DCH24 G>A 14:23,043,713 301.6 0.028482 No Data 
rs1803275 IL16 G>A 15:81,306,075 338.2 0.02965 
1f: eQTL + TF binding / 
DNase peak 
rs1052536 LIG3 C>T 17:35,004,556 550.1 0.52649 
1f: eQTL + TF binding / 
DNase peak 
 
a
 http://www.regulomedb.org/index 
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Table 3. Results of the case/control study in IMMeNSE. 
 
SNP  Gene 
Alleles Cases
b
 Controls
b
 Allelic model Codominant model 
(M/m)
a
 MM Mm mm MM Mm mm  OR
c
 95% CI
c
 p ORhet
c
 95% CI p ORhom
c
 95% CI p 
rs735794 SH3BP2 G/C 1431 1206 302 848 771 177 0.99 0.88-1.10 0.79 0.88 0.75-1.02 0.09 1.1 0.85-1.40 0.45 
rs12509103 MFAP3L A/T 2412 483 6 1484 278 1 1.04 0.86-1.27 0.64 1.04 0.85-1.27 0.69 1.72 0.15-18.8 0.66 
rs286595 MRPL22 C/T 799 1471 640 538 857 357 1.12 1.01-1.24 0.03 1.14 0.95-1.34 0.14 1.25 1.01-1.54 0.03 
rs1049623 DDR1 T/C 417 1333 1185 711 841 228 1.08 0.96-1.19 0.18 0.91 0.73-1.14 0.43 1.08 0.85-1.36 0.51 
rs1049633 DDR1 G/A 2465 409 3 1498 276 6 0.82 0.67-1.00 0.05 0.85 0.66-1.01 0.07 0.49 0.10-2.36 0.38 
rs1049628 DDR1 C/T 1781 932 139 1077 594 67 1.01 0.88-1.14 0.93 0.93 0.80-1.09 0.38 1.24 0.87-1.78 0.24 
rs1419881 TCF19 G/A 1124 1278 439 594 873 288 0.98 0.88-1.09 0.75 0.82 0.70-0.97 0.02 1.05 0.84-1.30 0.66 
rs13409 POU5F1 G/A 1194 1304 418 666 864 265 1.02 0.92-1.13 0.68 0.91 0.77-1.06 0.22 1.12 0.89-1.39 0.31 
rs1050239 SMPD1 G/A 1872 902 133 1069 593 93 0.92 0.81-1.04 0.22 0.92 0.78-1.07 0.29 0.89 0.62-1.22 0.42 
rs11628336 DCH24 G/A 1025 1375 533 646 853 293 0.99 0.89-1.10 0.91 0.96 0.82-1.24 0.63 1 0.81-1.24 0.98 
rs1803275 IL16 G/A 2567 379 21 1528 259 11 0.98 0.81-1.19 0.9 0.95 0.77-1.17 0.66 1.42 0.55-3.64 0.47 
rs1052536 LIG3 C/T 878 1402 654 590 825 365 1.01 0.90-1.11 0.89 1.05 0.89-1.24 0.57 1 0.81-1.23 0.96 
 
a
 M = major allele (i.e. more common in controls); m = minor allele (less common in controls). 
b
 Numbers may not add up to 100% due to genotyping failure, DNA depletion or covariate missing values. 
c
 OR: odds ratio; CI: confidence interval; ORhet: odds ratio obtained comparing heterozygotes with homozygotes for the major allele;  ORhom: odds 
ratio obtained comparing homozygotes for the minor allele with homozygotes for the major allele; all analyses were adjusted by age, sex and country 
of origin. 
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Table 4. Results of the meta-analysis for the allelic and codominant model. 
 
SNP Gene Model OR 95% CI p  p_heterogeneity 
rs13409 POUF51 Allelic 0.92 0.872-0.964 6.50x10
-4
 0.079 
  Codominant 0.85 0.762-0.938 2.00x10
-3
 0.068 
rs1049623 DDR1 Allelic 0.92 0.870-0.965 9.00x10
-4
 0.183 
  Codominant 0.86 0.765-0.956 6.00x10
-3
 0.504 
rs1049633 DDR1 Allelic 0.87 0.804-0.939 3.70x10
-4
 0.038 
  Codominant 0.69 0.582-0.819 2.14x10
-5
 0.599 
rs1419881 TCF19 Allelic 0.91 0.867-0.958 2.80x10
-4
 0.069 
  
Codominant 0.83 0.747-0.917 2.80x10
-4
 0.261 
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